abrdn Life Sciences Investors (NYSE:HQL) Increases Dividend to $0.62 Per Share

abrdn Life Sciences Investors (NYSE:HQL) declared a quarterly dividend on Tuesday, August 11th. Investors of record on Monday, August 24th will be paid a dividend of 0.62 per share on Monday, August 31st. This represents a c) dividend on an annualized basis and a yield of 11.7%. The ex-dividend date of this dividend is Monday, August 24th. This is a 10.7% increase from abrdn Life Sciences Investors’s previous quarterly dividend of $0.56.

abrdn Life Sciences Investors Price Performance

NYSE HQL traded up $0.11 during mid-day trading on Wednesday, reaching $21.21. 35,821 shares of the company’s stock traded hands, compared to its average volume of 126,918. abrdn Life Sciences Investors has a 1-year low of $13.44 and a 1-year high of $21.32. The company has a fifty day simple moving average of $19.11 and a 200-day simple moving average of $17.81.

Institutional Trading of abrdn Life Sciences Investors

Hedge funds have recently made changes to their positions in the stock. Geneos Wealth Management Inc. increased its stake in shares of abrdn Life Sciences Investors by 200.1% in the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after buying an additional 1,529 shares during the last quarter. Global Retirement Partners LLC boosted its stake in abrdn Life Sciences Investors by 187.8% during the 4th quarter. Global Retirement Partners LLC now owns 7,039 shares of the company’s stock valued at $118,000 after acquiring an additional 4,593 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in abrdn Life Sciences Investors during the 4th quarter worth $177,000. Evolve Private Wealth LLC acquired a new position in abrdn Life Sciences Investors during the 4th quarter worth $199,000. Finally, Independent Financial Group LLC bought a new stake in shares of abrdn Life Sciences Investors in the 1st quarter worth about $211,000. Institutional investors and hedge funds own 32.21% of the company’s stock.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.